非肌层浸润性膀胱癌的治疗现状  

Current treatment of non-muscle-invasive bladder cancer

作　　者：王兴[1] 崔曙[1] 谷君卿[1] 

机构地区：[1]川北医学院附属医院泌尿外科,四川南充637000

出　　处：《川北医学院学报》2013年第2期176-180,共5页Journal of North Sichuan Medical College

基　　金：四川省卫生厅科研项目(110318)

摘　　要：膀胱癌是泌尿系统最常见的恶性肿瘤之一,是一种直接威胁患者生存的疾病。非肌层浸润性膀胱癌(non-muscle invasive bladder cancer,NMIBC)占初发膀胱肿瘤的70%,包括Ta,T1和Tis。经尿道膀胱肿瘤电切术和术后膀胱内灌注化疗是目前NMIBC主要的治疗方式。虽经治疗,仍有相当一部分患者出现复发和进展。近年来,一些新的治疗手段和灌注方法不断应用于临床,为NMIBC的治疗开辟了新的思路。本文对非肌层浸润性膀胱癌的治疗现状进行综述,以期对临床防治膀胱肿瘤提供指导。Bladder cancer is one of the most common malignant tumors of the urinary system. It is a disease that threats the patients＇ survival. Non-muscle-invasive bladder cancer is accounted for 70% in primary bladder tumors,which include Ta,T1 and Tis. Tran- surethral resection of bladder tumor （TURBT） with postoperative instillation of chemotherapy is the main treatment for NMIBC. Al- though after treatment,there are a considerable proportion of patients occur recurrence and progression. In recent years,some new treat- ments and instillation methods have been applied to clinical treatment,which provide some new ideas for the methods of NMIBC. This review focuses on the current treatment of non-muscle invasive bladder cancer,which will provide a new guidance for clinical treatment.

关 键 词：非肌层浸润性膀胱癌 治疗现状 灌注 

分 类 号：R737[医药卫生—肿瘤]